Cargando…
The Prospective Randomized On-X Valve Anticoagulation Clinical Trial (PROACT): Lower is better, but is it good enough?
Due to their durability, mechanical prostheses are frequently used for aortic valve replacement (AVR) in young adults. However, these valves are thrombogenic and require lifelong anticoagulation. Over the last few decades, efforts have been made towards the lowering of INR targets in an effort to re...
Autores principales: | Bouhout, Ismail, El-Hamamsy, Ismail |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Magdi Yacoub Heart Foundation
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6472691/ https://www.ncbi.nlm.nih.gov/pubmed/31024944 http://dx.doi.org/10.21542/gcsp.2019.2 |
Ejemplares similares
-
RE-ALIGN: First trial of novel oral anticoagulant in patients with mechanical heart valves – The search continues
por: Shazly, Ahmed, et al.
Publicado: (2014) -
TAVI: New trials and registries offer further welcome evidence – U.S. CoreValve, CHOICE, and GARY
por: Pighi, Michele, et al.
Publicado: (2014) -
PARIS: A good start for exercise in HFPEF
por: Elamragy, Ahmed A.
Publicado: (2014) -
Anticoagulation in pulmonary arterial hypertension: Contemporary data from COMPERA registry
por: Said, Karim
Publicado: (2014) -
ENGAGE AF: Effective anticoagulation with factor Xa in next generation treatment of atrial fibrillation
por: Kaba, Riyaz A, et al.
Publicado: (2013)